DaVita/$DVA
1D1W1MYTD1Y5YMAX
Capital at risk
About DaVita
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
- Ticker
- $DVA
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 78,000
- Headquarters
- Denver, United States
- Website
- www.davita.com
DaVita Metrics
BasicAdvanced
$12B
15.12
$12.11
0.87
-
Price and volume
Market cap
$12B
Beta
0.87
52-week high
$247.49
52-week low
$101.00
Average daily volume
732K
Financial strength
Current ratio
1.467
Quick ratio
1.333
Long term debt to equity
11.904
Total debt to equity
12.42
Interest coverage (TTM)
3.65%
Profitability
EBITDA (TTM)
2,826.205
Gross margin (TTM)
32.36%
Net profit margin (TTM)
6.05%
Operating margin (TTM)
15.11%
Effective tax rate (TTM)
20.66%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
7.52%
Return on equity (TTM)
88.48%
Valuation
Price to earnings (TTM)
15.123
Price to revenue (TTM)
0.894
Price to book
-15.3
Price to tangible book (TTM)
-1.36
Price to free cash flow (TTM)
7.784
Free cash flow yield (TTM)
12.85%
Free cash flow per share (TTM)
23.52
Growth
Revenue change (TTM)
6.45%
Earnings per share change (TTM)
18.73%
3-year revenue growth (CAGR)
6.07%
10-year revenue growth (CAGR)
-0.24%
3-year earnings per share growth (CAGR)
33.80%
10-year earnings per share growth (CAGR)
21.55%
What the Analysts think about DaVita
Analyst ratings (Buy, Hold, Sell) for DaVita stock.
Analyst projections of the future price of DaVita stock.
Bulls say / Bears say
DaVita’s Q2 treatment growth reached 56 basis points, helped by lower patient mortality, and management now expects 2026 volume growth near the top of its previous range. Better survival can support recurring treatment volumes without relying solely on price increases. (The Motley Fool, DaVita Investor Relations)
Integrated Kidney Care delivered $40 million of adjusted operating income in Q2 and now manages about $5.8 billion of annualised medical spending. Management expects the platform to add roughly $20 million to full-year enterprise adjusted operating income, with further benefit from the timing of revenue recognition in Q4. (The Motley Fool, StockTitan)
DaVita plans to roll out expanded haemodialysis across its network after the MOTheR trial found it non-inferior to haemodiafiltration on mortality and major cardiovascular events. The near-term financial effect is limited, but a future mortality benefit could strengthen volumes and economics from 2028 onwards. (The Motley Fool)
DaVita’s revenue per treatment fell by about $2 sequentially as the commercial payer mix weakened after enhanced ACA subsidies expired. Management expects about a $40 million profit headwind in 2026 and a $70 million headwind in 2027, because new patients are also arriving with less commercial coverage. (The Motley Fool, DaVita Investor Relations)
The proposed 2027 ESRD payment update is below industry cost trends, according to management, leaving Medicare reimbursement at risk of squeezing margins. Phosphate binders moving into the bundled payment also reduced revenue per treatment, although DaVita supports the policy clinically. (The Motley Fool, DaVita Investor Relations)
Cost and balance-sheet pressure could limit upside from operational improvements: DaVita expects 2026 cost per treatment to rise by 1.25% to 2.25%, while leverage was 3.37 times EBITDA after issuing $500 million of incremental debt. Quarterly debt expense was $152 million, leaving less flexibility if payer pressure or Integrated Kidney Care results worsen. (The Motley Fool, StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 16 Sept 2026.
DaVita Financial Performance
Revenues and expenses
DaVita Earnings Performance
Company profitability
Upcoming events
No upcoming events
DaVita News
AllArticlesVideos
Funds containing DaVita
AllEURGBPUSD
Fund name | Fund size | $DVA weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.47% |
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.19% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.19% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.10% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.